Renal Cancer
European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021
Rational Development of Liquid Biopsy Analysis in Renal Cell Carcinoma.
November 29, 2021
Early Clinical Experience with Cabozantinib for Advanced Renal Cell Carcinoma in the UK: Real-World Treatment Pathways and Clinical Outcomes.
November 26, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.
November 26, 2021
Active Surveillance of Renal Masses: The Role of Radiology.
November 25, 2021
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial.
November 23, 2021
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
November 23, 2021
Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review.
November 22, 2021
Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas.
November 22, 2021
FDA Approves Merck’s Pembrolizumab as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma (RCC) Following Surgery
November 18, 2021